[fr] La curiethérapie prostatique, par implantation per
-
manente de grains radioactifs d’iode 125, offre aux patients
atteints d’un cancer localisé de la prostate une alternative
attractive au traitement chirurgical. La survie globale et la
survie sans récidive biochimique y sont superposables, mais le
profil de toxicité est différent. La plus grande opportunité de
préservation de la fonction érectile, la diminution du risque
d’incontinence et l’hospitalisation de jour peuvent être inté
-
ressantes pour le patient optant pour la curiethérapie. Par
contre, la présence d’un syndrome obstructif urinaire de
départ devrait orienter préférentiellement vers un traitement
chirurgical. Un patient doit pouvoir faire un choix éclairé
entre ces différentes possibilités thérapeutiques moyennant
une information transparente et complète. Dans cet exposé,
nous relatons notre expérience en curiethérapie par implants
permanents d’iode 125. La survie globale, la survie libre sans
récidive biochimique à long terme et la toxicité enregistrée
sont similaires à celles décrites dans la littérature.
Disciplines :
Oncologie
Auteur, co-auteur :
HERMESSE, Johanne ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
NICKERS, Philippe
REUL, Olivier
COUCKE, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
Langue du document :
Anglais
Titre :
LA CURIETHÉRAPIE PROSTATIQUE PAR IMPLANTS PERMANENTS D'IODE 125- résultats après 10 ans d'expérience au CHU de Liège
Date de publication/diffusion :
2014
Titre du périodique :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Maison d'édition :
Université de Liège. Revue Médicale de Liège, Liège, Belgique
Zelefsky, M.J., Hollister, T., Raben, A., Matthews, S., Wallner, K.E., Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer (2000) International Journal of Radiation Oncology Biology Physics, 47 (5), pp. 1261-1266. , DOI 10.1016/S0360-3016(00)00550-2, PII S0360301600005502
Zelefsky, M.J., Yamada, Y., Cohen, G.N., Shippy, A., Chan, H., Fridman, D., Zaider, M., Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer (2007) International Journal of Radiation Oncology Biology Physics, 67 (1), pp. 65-70. , DOI 10.1016/j.ijrobp.2006.08.030, PII S0360301606027969
Stone, N.N., Stock, R.G., Unger, P., Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer (2005) Journal of Urology, 173 (3), pp. 803-807. , DOI 10.1097/01.ju.0000152558.63996.29
Stock, R.G., Cesaretti, J.A., Stone, N.N., Disease-specific survival following the brachytherapy management of prostate cancer (2006) International Journal of Radiation Oncology Biology Physics, 64 (3), pp. 810-816. , DOI 10.1016/j.ijrobp.2005.09.005, PII S0360301605025964
Potters, L., Morgenstern, C., Calugaru, E., Fearn, P., Jassal, A., Presser, J., Mullen, E., 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer (2005) Journal of Urology, 173 (5), pp. 1562-1566. , DOI 10.1097/01.ju.0000154633.73092.8e
Ash, D., Al-Qaisieh, B., Bottomley, D., Carey, B., Joseph, J., The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer (2006) Radiotherapy and Oncology, 79 (2), pp. 185-189. , DOI 10.1016/j.radonc.2006.04.004, PII S016781400600154X
Sylvester, J.E., Grimm, P.D., Blasko, J.C., Millar, J., Orio III, P.F., Skoglund, S., Galbreath, R.W., Merrick, G., 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy
Seattle experience (2007) International Journal of Radiation Oncology Biology Physics, 67 (1), pp. 57-64. , DOI 10.1016/j.ijrobp.2006.07.1382, PII S036030160602774X
Zelefsky, M.J., Kuban, D.A., Levy, L.B., Potters, L., Beyer, D.C., Blasko, J.C., Moran, B.J., Horwitz, E.M., Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation (2007) International Journal of Radiation Oncology Biology Physics, 67 (2), pp. 327-333. , DOI 10.1016/j.ijrobp.2006.08.056, PII S0360301606028173
Guedea, F., Aguilo, F., Polo, A., Langley, S., Laing, R., Henderson, A., Aaltomaa, S., Nava, L., Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1-T2 prostate cancer (2006) Radiotherapy and Oncology, 80 (1), pp. 57-61. , DOI 10.1016/j.radonc.2006.06.004, PII S0167814006002465
Kupelian, P.A., Potters, L., Khuntia, D., Ciezki, J.P., Reddy, C.A., Reuther, A.M., Carlson, T.P., Klein, E.A., Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer (2004) International Journal of Radiation Oncology Biology Physics, 58 (1), pp. 25-33. , DOI 10.1016/S0360-3016(03)00784-3
Nag, S., Beyer, D., Friedland, J., Grimm, P., Nath, R., American brachytherapy society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer (1999) International Journal of Radiation Oncology Biology Physics, 44 (4), pp. 789-799. , DOI 10.1016/S0360-3016(99)00069-3, PII S0360301699000693
Ash, D., Flynn, A., Battermann, J., ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer (2000) Radiother Oncol, 57, pp. 315-321
Recommandations 2007 en uro-oncologie, AFU, SFRO, GETUG, SFP (2007) Progrès en Urologie, 17, pp. 1017-1159
Merrick, G.S., Wallner, K.E., Butler, W.M., Patient selection for prostate brachytherapy: More myth than fact (2004) Oncol (Williston Park), 18, pp. 445-457
Merrick, G.S., Butler, W.M., Wallner, K.E., Galbreath, R.W., Adamovich, E., Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL (2004) American Journal of Clinical Oncology: Cancer Clinical Trials, 27 (6), pp. 611-615. , DOI 10.1097/01.coc.0000135927.83639.5e
Zelefsky, M.J., Yamada, Y., Marion, C., Sim, S., Cohen, G., Ben-Porat, L., Silvern, D., Zaider, M., Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy (2003) International Journal of Radiation Oncology Biology Physics, 55 (4), pp. 956-963. , DOI 10.1016/S0360-3016(02)04142-1, PII S0360301602041421
(2006) Common Terminology Criteria for Adverse Events V3.0 (CTCAE), , Publish Date : August 9
Merrick, G.S., Wallner, K.E., Butler, W.M., Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer (2006) BJU Int, 98, pp. 324-328
Peschel, R.E., Khan, A., Colberg, J., Wilson, L.D., The effect of age on prostate implantation results (2006) Cancer Journal, 12 (4), pp. 305-308. , http://docserver.ingentaconnect.com/deliver/connect/jandb/15289117/v12n4/ s9.pdf?expires=1156319330&id=31235037&titleid=6269&accname= Elsevier&checksum=324B5B2536230B1423407DCA4598716E
Ferrer, M., Suárez, J.F., Guedea, F., Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer (2008) Int J Radiat Oncol Biol Phys, 72, pp. 421-432. , and Multicentric Spanish Group of Clinically Localized Prostate Cancer
